193 related articles for article (PubMed ID: 1891701)
21. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
[TBL] [Abstract][Full Text] [Related]
22. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
Soya K; Terasawa F; Okumura N
Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
[TBL] [Abstract][Full Text] [Related]
23. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain.
Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B
Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274
[TBL] [Abstract][Full Text] [Related]
24. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
[TBL] [Abstract][Full Text] [Related]
25. Fibrinogen Matsumoto III: a variant with gamma275 Arg-->Cys (CGC-->TGC)--comparison of fibrin polymerization properties with those of Matsumoto I (gamma364 Asp-->His) and Matsumoto II (gamma308 Asn-->Lys).
Terasawa F; Okumura N; Higuchi Y; Ishikawa S; Tozuka M; Ishida F; Kitano K; Katsuyama T
Thromb Haemost; 1999 May; 81(5):763-6. PubMed ID: 10365751
[TBL] [Abstract][Full Text] [Related]
26. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).
Meyer M; Kutscher G; Stürzebecher J; Riesener G; Lutze G
Thromb Res; 2003 Jan; 109(2-3):145-51. PubMed ID: 12706644
[TBL] [Abstract][Full Text] [Related]
27. Unusual A alpha 16Arg-->Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings.
Galanakis D; Spitzer S; Scharrer I
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):67-71. PubMed ID: 8457654
[TBL] [Abstract][Full Text] [Related]
28. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
29. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
30. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
31. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
[TBL] [Abstract][Full Text] [Related]
32. Functional analysis of recombinant Bbeta15C and Bbeta15A fibrinogens demonstrates that Bbeta15G residue plays important roles in FPB release and in lateral aggregation of protofibrils.
Hirota-Kawadobora M; Kani S; Terasawa F; Fujihara N; Yamauchi K; Tozuka M; Okumura N
J Thromb Haemost; 2005 May; 3(5):983-90. PubMed ID: 15869595
[TBL] [Abstract][Full Text] [Related]
33. Fibrinogen residue γAla341 is necessary for calcium binding and 'A-a' interactions.
Park R; Ping L; Song J; Hong SY; Choi TY; Choi JR; Gorkun OV; Lord ST
Thromb Haemost; 2012 May; 107(5):875-83. PubMed ID: 22437918
[TBL] [Abstract][Full Text] [Related]
34. B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'.
Okumura N; Terasawa F; Haneishi A; Fujihara N; Hirota-Kawadobora M; Yamauchi K; Ota H; Lord ST
J Thromb Haemost; 2007 Dec; 5(12):2352-9. PubMed ID: 17922804
[TBL] [Abstract][Full Text] [Related]
35. [Fibrinogen Bern I and fibrinogen Bern II: 2 hereditary fibrinogen variants with diverse biochemical properties].
Rupp C; Kuyas C; Haeberli A; Furlan M; von Fliedner V; Beck EA
Schweiz Med Wochenschr; 1981 Oct; 111(41):1543-5. PubMed ID: 7313627
[TBL] [Abstract][Full Text] [Related]
36. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
Schreiber WE; Schmer G
Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
[TBL] [Abstract][Full Text] [Related]
37. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
Lane DA; Cuddigan B; VanRoss M; Kakkar VV
Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
[TBL] [Abstract][Full Text] [Related]
38. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp).
Brennan SO; Hammonds B; George PM
J Clin Invest; 1995 Dec; 96(6):2854-8. PubMed ID: 8675656
[TBL] [Abstract][Full Text] [Related]
39. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.
Andes WA; Chavin SI; Beltran G; Stuckey WJ
Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812
[TBL] [Abstract][Full Text] [Related]
40. A new genetic fibrinogen variant (fibrinogen Erfurt I). Structurally characterized by an abnormal B beta-chain and present both in plasma and platelets.
Meyer M; Schellenberg I; Vogel G; Bischoff I
Thromb Haemost; 1988 Apr; 59(2):138-42. PubMed ID: 3388290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
